352 related articles for article (PubMed ID: 36562927)
21. A strategy using mesoporous polymer nanospheres as nanocarriers of Bcl-2 siRNA towards breast cancer therapy.
Wu X; Zheng Y; Yang D; Chen T; Feng B; Weng J; Wang J; Zhang K; Zhang X
J Mater Chem B; 2019 Jan; 7(3):477-487. PubMed ID: 32254735
[TBL] [Abstract][Full Text] [Related]
22. Silencing of the IKKε gene by siRNA inhibits invasiveness and growth of breast cancer cells.
Qin B; Cheng K
Breast Cancer Res; 2010; 12(5):R74. PubMed ID: 20863366
[TBL] [Abstract][Full Text] [Related]
23. Multifunctional hybrid nanoparticles as magnetic delivery systems for siRNA targeting the HER2 gene in breast cancer cells.
Cristofolini T; Dalmina M; Sierra JA; Silva AH; Pasa AA; Pittella F; Creczynski-Pasa TB
Mater Sci Eng C Mater Biol Appl; 2020 Apr; 109():110555. PubMed ID: 32228895
[TBL] [Abstract][Full Text] [Related]
24. Curtailing overexpression of E2F3 in breast cancer using siRNA (E2F3)-based gene silencing.
Vimala K; Sundarraj S; Sujitha MV; Kannan S
Arch Med Res; 2012 Aug; 43(6):415-22. PubMed ID: 22960857
[TBL] [Abstract][Full Text] [Related]
25. Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs.
Li YT; Chua MJ; Kunnath AP; Chowdhury EH
Int J Nanomedicine; 2012; 7():2473-81. PubMed ID: 22701315
[TBL] [Abstract][Full Text] [Related]
26. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
[TBL] [Abstract][Full Text] [Related]
27. Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles.
Sivakumar P; Kim S; Kang HC; Shim MS
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1543. PubMed ID: 30070426
[TBL] [Abstract][Full Text] [Related]
28. Targeted silencing of Survivin in cancer cells by siRNA loaded chitosan magnetic nanoparticles.
Unsoy G; Gunduz U
Expert Rev Anticancer Ther; 2016 Jul; 16(7):789-97. PubMed ID: 27130312
[TBL] [Abstract][Full Text] [Related]
29. Multifunctional peptide-lipid nanocomplexes for efficient targeted delivery of DNA and siRNA into breast cancer cells.
Wan Y; Dai W; Nevagi RJ; Toth I; Moyle PM
Acta Biomater; 2017 Sep; 59():257-268. PubMed ID: 28655658
[TBL] [Abstract][Full Text] [Related]
30. Novel polyacrylate-based cationic nanoparticles for survivin siRNA delivery combined with mitoxantrone for treatment of breast cancer.
Arami S; Mahdavi M; Rashidi MR; Fathi M; Hejazi MS; Samadi N
Biologicals; 2016 Nov; 44(6):487-496. PubMed ID: 27712979
[TBL] [Abstract][Full Text] [Related]
31. Glucose-linked sub-50-nm unimer polyion complex-assembled gold nanoparticles for targeted siRNA delivery to glucose transporter 1-overexpressing breast cancer stem-like cells.
Yi Y; Kim HJ; Zheng M; Mi P; Naito M; Kim BS; Min HS; Hayashi K; Perche F; Toh K; Liu X; Mochida Y; Kinoh H; Cabral H; Miyata K; Kataoka K
J Control Release; 2019 Feb; 295():268-277. PubMed ID: 30639386
[TBL] [Abstract][Full Text] [Related]
32. Functional nanostructures for effective delivery of small interfering RNA therapeutics.
Hong CA; Nam YS
Theranostics; 2014; 4(12):1211-32. PubMed ID: 25285170
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of STAT3, β-Catenin, and Notch-1 by Single and Combinations of siRNA Treatment Enhance Chemosensitivity of Wild Type and Doxorubicin Resistant MCF7 Breast Cancer Cells to Doxorubicin.
Alshaer W; Alqudah DA; Wehaibi S; Abuarqoub D; Zihlif M; Hatmal MM; Awidi A
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357721
[TBL] [Abstract][Full Text] [Related]
34. Co-delivery of curcumin and Bcl-2 siRNA to enhance therapeutic effect against breast cancer cells using PEI-functionalized PLGA nanoparticles.
Mohammad Gholinia Sarpoli L; Zare-Karizi S; Heidari E; Hasanzadeh A; Bayandori M; Azedi F; Hamblin MR; Karimi M
Pharm Dev Technol; 2022 Sep; 27(7):785-793. PubMed ID: 36043390
[TBL] [Abstract][Full Text] [Related]
35. A systematic comparison of lipopolymers for siRNA delivery to multiple breast cancer cell lines: In vitro studies.
Aliabadi HM; Bahadur K C R; Bousoik E; Hall R; Barbarino A; Thapa B; Coyle M; Mahdipoor P; Uludağ H
Acta Biomater; 2020 Jan; 102():351-366. PubMed ID: 31760224
[TBL] [Abstract][Full Text] [Related]
36. Stimuli-responsive hybrid nanocarriers developed by controllable integration of hyperbranched PEI with mesoporous silica nanoparticles for sustained intracellular siRNA delivery.
Prabhakar N; Zhang J; Desai D; Casals E; Gulin-Sarfraz T; Näreoja T; Westermarck J; Rosenholm JM
Int J Nanomedicine; 2016; 11():6591-6608. PubMed ID: 27994460
[TBL] [Abstract][Full Text] [Related]
37. Reduction/photo dual-responsive polymeric prodrug nanoparticles for programmed siRNA and doxorubicin delivery.
Wu M; Li J; Lin X; Wei Z; Zhang D; Zhao B; Liu X; Liu J
Biomater Sci; 2018 May; 6(6):1457-1468. PubMed ID: 29770812
[TBL] [Abstract][Full Text] [Related]
38. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
39. Magnetic nanocarriers for the specific delivery of siRNA: Contribution of breast cancer cells active targeting for down-regulation efficiency.
Bruniaux J; Allard-Vannier E; Aubrey N; Lakhrif Z; Ben Djemaa S; Eljack S; Marchais H; Hervé-Aubert K; Chourpa I; David S
Int J Pharm; 2019 Oct; 569():118572. PubMed ID: 31352052
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
